Fenofibrate Bioequivalence Study (0767-031)

An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects

This study will determine definitive bioequivalence of the United States (U.S.) and United Kingdom (UK) formulations of fenofibrate following administration of single doses in healthy adult subjects.

Inclusion Criteria:

• Subject is in good health
• Subject is willing to follow all study guidelines

Exclusion Criteria:

• Subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study or make participation unsafe
• Female subject is receiving oral contraceptives or hormone replacement therapy